News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,721 Results
Type
Article (14720)
Company Profile (284)
Press Release (253717)
Section
Business (80278)
Career Advice (155)
Deals (13336)
Drug Delivery (35)
Drug Development (51643)
Employer Resources (31)
FDA (5824)
Job Trends (5276)
News (146380)
Policy (10209)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (8)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (946)
Accelerated approval (2)
Adcomms (14)
Allergies (48)
Alliances (21891)
ALS (53)
Alzheimer's disease (809)
Antibody-drug conjugate (ADC) (82)
Approvals (5825)
Artificial intelligence (103)
Autoimmune disease (7)
Automation (5)
Bankruptcy (103)
Best Places to Work (4707)
BIOSECURE Act (5)
Biosimilars (35)
Biotechnology (233)
Bladder cancer (43)
Brain cancer (20)
Breast cancer (133)
Cancer (1240)
Cardiovascular disease (92)
Career advice (135)
Career pathing (2)
CAR-T (101)
Cell therapy (295)
Cervical cancer (6)
Clinical research (41641)
Collaboration (467)
Compensation (189)
Complete response letters (13)
COVID-19 (1036)
CRISPR (33)
C-suite (127)
Cystic fibrosis (75)
Data (1220)
Denatured (11)
Depression (26)
Diabetes (110)
Diagnostics (1327)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (73)
Drug pricing (27)
Drug shortages (3)
Duchenne muscular dystrophy (60)
Earnings (29714)
Editorial (16)
Employer branding (4)
Employer resources (29)
Events (48503)
Executive appointments (372)
FDA (6369)
Featured Employer (34)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (431)
Gene editing (79)
Generative AI (9)
Gene therapy (210)
GLP-1 (348)
Government (1120)
Grass and pollen (2)
Guidances (18)
Healthcare (6710)
Huntington's disease (21)
IgA nephropathy (18)
Immunology and inflammation (70)
Indications (16)
Infectious disease (1090)
Inflammatory bowel disease (107)
Inflation Reduction Act (8)
Influenza (16)
Intellectual property (50)
Interviews (18)
IPO (7310)
IRA (11)
Job creations (871)
Job search strategy (129)
Kidney cancer (7)
Labor market (3)
Layoffs (208)
Leadership (2)
Legal (1392)
Liver cancer (39)
Lung cancer (182)
Lymphoma (78)
Machine learning (1)
Management (7)
Manufacturing (105)
MASH (46)
Medical device (2592)
Medtech (2593)
Mergers & acquisitions (6273)
Metabolic disorders (330)
Multiple sclerosis (45)
NASH (13)
Neurodegenerative disease (51)
Neuropsychiatric disorders (21)
Neuroscience (1139)
NextGen: Class of 2025 (2046)
Non-profit (871)
Northern California (1416)
Now hiring (19)
Obesity (171)
Opinion (98)
Ovarian cancer (50)
Pain (38)
Pancreatic cancer (49)
Parkinson's disease (91)
Partnered (6)
Patents (95)
Patient recruitment (56)
Peanut (35)
People (25533)
Pharmaceutical (49)
Pharmacy benefit managers (5)
Phase I (14713)
Phase II (19352)
Phase III (12299)
Pipeline (578)
Podcasts (41)
Policy (30)
Postmarket research (858)
Preclinical (6136)
Press Release (30)
Prostate cancer (50)
Psychedelics (35)
Radiopharmaceuticals (211)
Rare diseases (256)
Real estate (1422)
Recruiting (12)
Regulatory (8634)
Reports (14)
Research institute (984)
Resumes & cover letters (17)
Rett syndrome (2)
RNA editing (1)
RSV (10)
Schizophrenia (52)
Series A (88)
Series B (51)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1252)
Special edition (10)
Sponsored (13)
Startups (1979)
State (1)
Stomach cancer (7)
Supply chain (17)
The Weekly (30)
United States (11186)
Vaccines (205)
Venture capitalists (27)
Webinars (7)
Weight loss (97)
Women's health (15)
Worklife (2)
Date
Today (110)
Last 7 days (483)
Last 30 days (1719)
Last 365 days (20678)
2025 (3344)
2024 (20831)
2023 (22765)
2022 (27254)
2021 (28265)
2020 (23778)
2019 (16605)
2018 (11990)
2017 (14080)
2016 (12096)
2015 (14564)
2014 (10481)
2013 (7508)
2012 (7561)
2011 (7621)
2010 (7431)
Location
Africa (149)
Alabama (37)
Alaska (2)
Arizona (50)
Arkansas (5)
Asia (17462)
Australia (2956)
California (3221)
Canada (993)
China (289)
Colorado (124)
Connecticut (135)
Delaware (81)
Europe (37569)
Florida (378)
Georgia (94)
Idaho (16)
Illinois (204)
India (6)
Indiana (79)
Iowa (1)
Japan (64)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (10)
Maryland (422)
Massachusetts (2552)
Michigan (69)
Minnesota (124)
Mississippi (1)
Missouri (25)
Montana (14)
Nebraska (4)
Nevada (14)
New Hampshire (13)
New Jersey (832)
New Mexico (11)
New York (885)
North Carolina (495)
North Dakota (4)
Northern California (1416)
Ohio (102)
Oklahoma (8)
Oregon (21)
Pennsylvania (599)
Puerto Rico (1)
Rhode Island (12)
South America (208)
South Carolina (3)
Southern California (1252)
Tennessee (24)
Texas (361)
Utah (45)
Virginia (67)
Washington D.C. (27)
Washington State (304)
Wisconsin (13)
268,721 Results for "checkpoint therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
December 16, 2024
·
15 min read
Genetown
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
Checkpoint Therapeutics, Inc. today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) resubmission strategy for cosibelimab.
June 24, 2024
·
5 min read
Business
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
Checkpoint Therapeutics, Inc. today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates.
May 10, 2024
·
9 min read
Press Releases
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
November 12, 2024
·
10 min read
Business
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.
March 22, 2024
·
10 min read
Genetown
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics, Inc. today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET.
May 13, 2024
·
1 min read
Genetown
GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate Immune Checkpoint and Cancer Immunotherapy Target
GV20 Therapeutics today announced the publication of a peer-reviewed article titled, " IGSF8 is an innate immune checkpoint and cancer immunotherapy target " in the journal Cell.
April 24, 2024
·
2 min read
Press Releases
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint Inhibitor
February 11, 2025
·
3 min read
Stomach cancer
FDA Sets Adcomm Meeting to Assess Checkpoint Inhibitors in Stomach Cancer Using PD-L1
The Oncologic Drugs Advisory Committee in a Sept. 26 meeting will discuss whether the regulator should restrict approval of checkpoint inhibitors based on PD-L1 expression levels.
August 23, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Valora Therapeutics Raises $30 Million Seed Financing from Top Investors to Transform Immunotherapy with a Novel Glyco-immune Checkpoint Platform
November 20, 2024
·
3 min read
1 of 26,873
Next
